These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 4736076)

  • 1. Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests.
    Horst WD; Pool WR; Spiegel HE
    Eur J Pharmacol; 1973 Mar; 21(3):337-42. PubMed ID: 4736076
    [No Abstract]   [Full Text] [Related]  

  • 2. Synthesis and antireserpine activity of peptides of L-dopa.
    Felix AM; Winter DP; Wang SS; Kulesha ID; Pool WR; Hane DL; Sheppard H
    J Med Chem; 1974 Apr; 17(4):422-6. PubMed ID: 4857423
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of L-DOPA on conditioned avoidance responding after behavioural suppression by alpha-methyltyrosine or reserpine in mice.
    Ahlenius S
    Neuropharmacology; 1974 Aug; 13(8):729-39. PubMed ID: 4444759
    [No Abstract]   [Full Text] [Related]  

  • 4. L-DOPA: chemical modifications and biological evaluation.
    Brossi A; Pool W; Sheppard H; Burns JJ; Kaiser A; Bigler R; Bartholini G; Pletscher A
    Adv Neurol; 1974; 5():291-3. PubMed ID: 4474795
    [No Abstract]   [Full Text] [Related]  

  • 5. Alpha-methyldopamine derivatives. Synthesis and pharmacology.
    Borgman RJ; Baylor MR; McPhillips JJ; Stitzel RE
    J Med Chem; 1974 Apr; 17(4):427-30. PubMed ID: 4830540
    [No Abstract]   [Full Text] [Related]  

  • 6. Potentiation of effects of L-dopa on conditioned avoidance behavior by inhibition of extracerebral dopa decarboxylase.
    Seiden LS; Martin TW
    Physiol Behav; 1971 Apr; 6(4):453-8. PubMed ID: 5148757
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacological & biochemical characterization of antiparkinson drugs in reserpinized mice.
    David J; Kaul CL; Grewal RS
    Indian J Exp Biol; 1979 Aug; 17(8):760-4. PubMed ID: 575644
    [No Abstract]   [Full Text] [Related]  

  • 8. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
    Lotti VJ; Porter CC
    J Pharmacol Exp Ther; 1970 Apr; 172(2):406-15. PubMed ID: 5441162
    [No Abstract]   [Full Text] [Related]  

  • 9. Behavior and biochemical effects of preferentially protecting monoamines in the brain against the action of reserpine.
    Butcher LL; Rhodes DL; Yuwiler A
    Eur J Pharmacol; 1972 May; 18(2):204-12. PubMed ID: 4537669
    [No Abstract]   [Full Text] [Related]  

  • 10. Dopa reversal of reserpine enhancement of audiogenic seizure susceptibility in mice.
    Boggan WO; Seiden LS
    Physiol Behav; 1971 Mar; 6(3):215-7. PubMed ID: 5125476
    [No Abstract]   [Full Text] [Related]  

  • 11. DOPA effects on motility in mice; potentiation by MK 485 and dexchlorpheniramine.
    Strömberg U
    Psychopharmacologia; 1970 Aug; 18(1):58-67. PubMed ID: 5535577
    [No Abstract]   [Full Text] [Related]  

  • 12. Dopa-induced locomotor stimulation after inhibition of extracerebral decarboxylase.
    Bartholini G; Blum JE; Pletscher A
    J Pharm Pharmacol; 1969 May; 21(5):297-301. PubMed ID: 4390121
    [No Abstract]   [Full Text] [Related]  

  • 13. Behavioral and biochemical effects of L-dopa after peripheral decarboxylase inhibition.
    Butcher LL; Engel J
    Brain Res; 1969 Sep; 15(1):233-42. PubMed ID: 5807767
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pharmacological study of amantadine, a new antiparkinson drug].
    Mori J; Sato Y; Oashi T; Hitomi M
    Nihon Yakurigaku Zasshi; 1974 Jan; 70(1):119-26. PubMed ID: 4858046
    [No Abstract]   [Full Text] [Related]  

  • 15. L-Dopa and imipramine: biochemical and behavioral interaction.
    Friedman E; Gershon S
    Eur J Pharmacol; 1972 May; 18(2):183-8. PubMed ID: 5037381
    [No Abstract]   [Full Text] [Related]  

  • 16. Reversal of the reserpine-induced suppression of the conditioned avoidance response by L-dopa: correlation of behavioral and biochemical differences in two strains of mice.
    Seiden LS; Peterson DD
    J Pharmacol Exp Ther; 1968 Feb; 159(2):422-8. PubMed ID: 5638661
    [No Abstract]   [Full Text] [Related]  

  • 17. The production of an alternative laboratory model of the Parkinson syndrome using a new benzylimidoylurea derivative LON 954.
    Coward DM; Doggett NS
    Psychopharmacology (Berl); 1977 Apr; 52(2):165-71. PubMed ID: 407600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa in the treatment of Parkinsonism.
    Cotzias GC
    JAMA; 1971 Dec; 218(13):1903-8. PubMed ID: 5171066
    [No Abstract]   [Full Text] [Related]  

  • 19. Restoration of locomotor activity in mice by low L-DOPA doses after suppression by alpha-methyltyrosine but not by reserpine.
    Ahlenius S; Andén NE; Engel J
    Brain Res; 1973 Nov; 62(1):189-99. PubMed ID: 4358099
    [No Abstract]   [Full Text] [Related]  

  • 20. Effects of L-dopa on accumulation and efflux of monoamines in particles of rat brain homogenates.
    Ng LK; Colburn RW; Kopin IJ
    J Pharmacol Exp Ther; 1972 Nov; 183(2):316-25. PubMed ID: 5083548
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.